Lorem ipsum dolor sit amet, consectetur adipiscing elit

Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum

Lorem ipsum

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris. Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

The unmet clinical need

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris.

Lorem ipsum dolor sit
amet, consectetur ad
ipisicing elit, sed do
eiusmod tempor incididunt
ut labore et
dolore magna aliqua. Ut enim ad min
im veniam, quis nostrud exercitation ullamco laboris.

Latest press releases

Annexin advances the NEXUS study to include patients who received an anti-VEGF injection

Annexin Pharmaceuticals AB announces a next patient cohort in the NEXUS study. The company continues to study the effects of the drug candidate vanexin (formerly ANXV) in patients with retinal…

Latest press releases

Annexin Pharmaceuticals receives the International Nonproprietary Name (INN) vanexin for the drug candidate ANXV

Annexin Pharmaceuticals AB today announces that the World Health Organization (WHO) has selected vanexin as the proposed International Nonproprietary Name (INN) for the company's drug candidate ANXV. It is an…

Latest press releases

Annexin updates on nine patients treated in NEXUS study

Annexin Pharmaceuticals AB announces an update on the patient recruitment status in the NEXUS study. As of today, six patients with retinal vein occlusion (RVO) and three patients with diabetic…

Latest press releases

Annexin’s rights issue 98 percent subscribed

NOT INTENDED FOR DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, RUSSIA, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR NEW ZEALAND…